Physician profile
Daniel Gonzalez
NPI 1891384905
$1,199.89
in general payments reported to CMS, 2019-2025
11 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $776 · 2022: $200 · 2024: $70.62 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $299.74 | 2021-2025 | Rexulti |
| Abbvie INC. | $268.76 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $177.37 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.91 | 2021 | |
| Corium, LLC | $91.94 | 2025 | Azstarys |
| Medtronic, INC. | $54.00 | 2022 | |
| Alkermes, INC. | $44.59 | 2021-2025 | Lybalvi |
| Neurocrine Biosciences, INC. | $44.44 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $32.26 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.43 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.45 | 2025 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.